Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
ChinaIPO:
05 August 2021Website:
http://www.ysbiopharm.comNext earnings report:
30 October 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 23:38:44 GMTDividend
Analysts recommendations
Institutional Ownership
LSB Latest News
GAITHERSBURG, Md. , Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a Phase III clinical trial (the "Trial") by the National Medical Products Administration (NMPA) in China to explore the immunogenicity and safety of a simplified four-dose regimen for its YSJA rabies vaccine which is the first generation of the Company's rabies vaccine and has sold more than 100M doses since its market approval.
GAITHERSBURG, Md. , Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining the Company's strong execution and positive business momentum.
GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.
Gross margin increased to 79.5%; product pipeline continues to advance Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025 GAITHERSBURG, Md. , Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.
What type of business is LakeShore Biopharma?
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
What sector is LakeShore Biopharma in?
LakeShore Biopharma is in the Healthcare sector
What industry is LakeShore Biopharma in?
LakeShore Biopharma is in the Biotechnology industry
What country is LakeShore Biopharma from?
LakeShore Biopharma is headquartered in China
When did LakeShore Biopharma go public?
LakeShore Biopharma initial public offering (IPO) was on 05 August 2021
What is LakeShore Biopharma website?
https://www.ysbiopharm.com
Is LakeShore Biopharma in the S&P 500?
No, LakeShore Biopharma is not included in the S&P 500 index
Is LakeShore Biopharma in the NASDAQ 100?
No, LakeShore Biopharma is not included in the NASDAQ 100 index
Is LakeShore Biopharma in the Dow Jones?
No, LakeShore Biopharma is not included in the Dow Jones index
When was LakeShore Biopharma the previous earnings report?
No data
When does LakeShore Biopharma earnings report?
The next expected earnings date for LakeShore Biopharma is 30 October 2024